SHERIDAN, WYOMING – May 7, 2025 – Edwards Lifesciences (NYSE: EW), a global leader in structural heart innovation, will announce its operating results for the first quarter ending March 31, 2025, after market close on Wednesday, April 23, 2025. The company will then host a conference call at 5:00 p.m. ET that same day to discuss these results in detail, providing insights into its financial performance and future strategic direction.
Conference Call Details and Participation
Edwards Lifesciences invites all interested parties to join the conference call. To participate, dial (877) 704-2848 or (201) 389-0893. For those unable to attend live, the conference call will be available for replay on the "Investor Relations" section of the Edwards website at ir.edwards.com.
About Edwards Lifesciences
As a pioneer in structural heart technologies, Edwards Lifesciences is committed to delivering life-saving innovations to patients worldwide. With a strong focus on advancing heart valve disease treatment, the company works closely with clinicians and healthcare professionals to ensure its groundbreaking products address the most critical needs of patients.
Edwards Lifesciences' solutions are backed by world-class clinical evidence, which demonstrates their effectiveness in improving patient outcomes. The company's innovations are driven by its patient-focused culture, emphasizing the importance of quality and precision in every aspect of product development and patient care.
Strategic Impact and Market Relevance
With a legacy of more than six decades, Edwards Lifesciences continues to lead the field of structural heart solutions. The company’s ongoing advancements in technology contribute to the global evolution of heart disease treatment. As healthcare systems worldwide look to address the rising incidence of cardiovascular diseases, Edwards Lifesciences remains at the forefront, providing both innovative products and comprehensive evidence to support their adoption.
Key strategic advantages include:
- Leading Heart Valve Technologies: Edwards Lifesciences is known for its pioneering products, such as transcatheter heart valves, which are revolutionizing how heart diseases are treated.
- Patient-Centered Focus: The company's culture ensures that patient outcomes are always at the forefront of its product development and clinical research.
- Global Reach and Partnerships: Edwards collaborates with healthcare providers, clinicians, and patients globally to ensure its solutions meet the diverse needs of heart patients.
Looking Ahead: What’s Next for Edwards Lifesciences?
Edwards Lifesciences continues to expand its portfolio, bringing new technologies and solutions that promise to redefine cardiovascular care. The company’s commitment to improving patient lives drives its ongoing innovation, ensuring it remains a key player in the evolving healthcare landscape.
For more information on Edwards Lifesciences’ products, upcoming financial reports, and strategic initiatives, visit www.edwards.com.